Science Corporation, founded by former Neuralink president Max Hodak, has announced the European commercial launch of its PRIMA system. This groundbreaking brain-computer interface is the first clinically proven treatment to restore functional vision for patients with geographic atrophy from age-related macular degeneration. The launch marks a significant milestone for the company and the broader field of neurotechnology, offering new hope to millions.
A New Hope for Vision Restoration
Age-related macular degeneration is a leading cause of blindness, affecting over five million people globally by destroying central vision. This condition robs individuals of the ability to read, recognize faces, and maintain their independence. PRIMA is the first and only device to receive CE marking for restoring detailed form vision in these patients.
The PRIMA system consists of a tiny, 2x2 millimeter photovoltaic implant and a pair of specialized glasses. During a brief outpatient procedure, the chip is placed under the retina at the back of the eye. The glasses then project near-infrared light onto the implant, which converts the light into electrical signals that stimulate the retina.
Clinical Validation and Regulatory Milestones
The device's efficacy was validated in a multi-center clinical trial involving 38 patients, with results published in the New England Journal of Medicine. On average, patients experienced a visual acuity improvement equivalent to reading five additional lines on an eye chart. A remarkable 84% of participants regained the ability to read letters, numbers, and words, demonstrating a restoration of functional vision.
This successful clinical performance has led to significant regulatory achievements for Science Corporation. The company has secured a CE mark, authorizing PRIMA for commercial use in 30 European countries. In the United States, the device has received both Breakthrough Device and Humanitarian Use Device designations from the FDA, signaling an expedited path toward market entry.
Commercial Strategy and Future Ambitions
With regulatory approval secured in Europe, the company is now focused on its commercial rollout, beginning in Germany. Science Corporation is actively working with healthcare providers on reimbursement strategies for the device, which is expected to cost several hundred thousand dollars. The first commercial implant is anticipated to take place as early as September, marking a pivotal moment for the company.
CEO Max Hodak views the commercialization of PRIMA as a critical step toward building a sustainable business in the neurotechnology sector. This vision restoration product provides a tangible revenue stream that is essential for funding the company's more ambitious long-term research. This strategic approach aims to avoid the funding challenges that can plague deep-tech ventures while delivering immediate patient benefits.
The company is already planning future enhancements for the PRIMA system, including a more advanced chip and improved glasses. The current design requires a separate battery pack, but the goal is to evolve the hardware into a more streamlined form factor. This iterative development will continue to improve the patient experience and the device's overall capabilities over time.
The launch of PRIMA represents a landmark achievement, transforming a sophisticated brain-computer interface from a research concept into a life-changing commercial medical device. It provides a powerful new treatment for a debilitating form of blindness and establishes Science Corporation as a leader in the field. This success not only offers immediate hope to patients but also builds a foundation for the company's future innovations in bio-hybrid technology.